Novartis Vaccines & Diagnostics, Gmbh

Sansan Lin

David Y Chien

Angelica Medina-Selby

Doris Guenzi Coit

Carlos George-Nascimento

Laura Tandeske

Celine Hu

Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.

HCV multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof

Modified HCV non-structural proteins are described. The proteins include modified NS3 domains such that proteolytic activity of the NS3 molecule is inhibited. The modified proteins retain conformational epitopes. HCV immunoassays including the modified NS3 molecules are also described.

HCV non-structural protein mutants and uses thereof

Growing community of inventors

Albany, CA, United States of America

Sansan Lin